Glucosado Braun

Glucosado Braun is a sterile intravenous solution that contains glucose monohydrate as its sole active ingredient. It is supplied in a parenteral formulation without a specified strength, intended for use under medical supervision. Classified as a carbohydrate solution and volume expander, Glucosado Braun is marketed in the European Union and requires a prescription. The product is administered by injection into a vein to provide exogenous glucose and support fluid balance.

Glucosado Braun is indicated for clinical situations where rapid glucose supplementation or fluid replacement is required. It is commonly employed in hospital settings to address metabolic and volume needs in patients.

- Treatment of acute hypoglycemia when oral glucose is not feasible. - Provision of carbohydrate calories in parenteral nutrition regimens. - Volume expansion in patients with fluid loss or dehydration. - Support of hemodynamic stability during surgery or critical care. - Dilution and compatibility agent for intravenous drug admixtures.

The safety profile of Glucosado Braun reflects the expected pharmacologic actions of intravenous glucose solutions, with most reactions being mild and reversible.

Common: - Transient elevation of blood glucose levels that typically normalize with continued monitoring. - Mild irritation or erythema at the infusion site, often resolving without intervention. - Nausea or mild abdominal discomfort occurring during or shortly after infusion. - Small shifts in serum electrolytes, most commonly a mild decrease in sodium concentration.

Serious: - Marked hyperglycemia that may precipitate osmotic diuresis and dehydration. - Fluid overload leading to signs of pulmonary congestion or edema. - Allergic reactions ranging from skin rash to rare anaphylactic responses.

When using Glucosado Braun, clinicians should evaluate patient-specific factors and monitor relevant parameters to minimize risks.

- Assess baseline blood glucose and adjust infusion rate to avoid hyperglycemia. - Monitor fluid balance and weight to prevent volume overload, especially in cardiac or renal impairment. - Check serum electrolytes before and during therapy, correcting abnormalities as needed. - Use caution in patients with uncontrolled diabetes mellitus or insulin resistance. - Avoid rapid infusion in neonates and infants due to risk of metabolic disturbances. - Consider pregnancy status; limited data are available regarding fetal safety. - Discontinue if signs of allergic reaction develop.

Glucosado Braun may interact with other intravenous agents or conditions that affect glucose metabolism, requiring careful coordination.

Avoid: - Co-administration with high-concentration dextrose solutions that could cause severe hyperglycemia. - Simultaneous infusion with potassium chloride without appropriate monitoring, due to risk of hyperkalemia.

Use with caution: - Concurrent use of insulin therapy; glucose infusion may necessitate dose adjustments. - Administration alongside diuretics that influence fluid status, requiring close assessment of volume balance. - Use in patients receiving other volume expanders (e.g., albumin) to avoid cumulative fluid overload.